Analysts See $0.28 EPS for A-Mark Precious Metals (AMRK); Arbutus Biopharma (ABUS) Had 4 Bulls



September 4, 2017 – By Migdalia James

Analysts expect A-Mark Precious Metals Inc (NASDAQ:AMRK) to report $0.28 EPS on September, 20.They anticipate $0.13 EPS change or 86.67% from last quarter’s $0.15 EPS. AMRK’s profit would be $1.97M giving it 15.52 P/E if the $0.28 EPS is correct. After having $0.16 EPS previously, A-Mark Precious Metals Inc’s analysts see 75.00% EPS growth. The stock increased 1.40% or $0.24 on September 1, reaching $17.38. About 34,174 shares traded or 48.76% up from the average. A-Mark Precious Metals Inc (NASDAQ:AMRK) has risen 4.68% since September 4, 2016 and is uptrending. It has underperformed by 12.02% the S&P500.

Among 5 analysts covering Arbutus Biopharma (NASDAQ:ABUS), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Arbutus Biopharma had 15 analyst reports since August 7, 2015 according to SRatingsIntel. As per Friday, August 5, the company rating was downgraded by Leerink Swann. Chardan Capital Markets downgraded it to “Neutral” rating and $3 target in Tuesday, December 13 report. The firm has “Outperform” rating given on Friday, November 6 by RBC Capital Markets. The firm has “Buy” rating given on Tuesday, April 4 by Chardan Capital Markets. On Thursday, June 16 the stock rating was upgraded by Chardan Capital Markets to “Neutral”. The stock has “Neutral” rating by Chardan Capital Markets on Friday, October 14. Wedbush initiated Arbutus Biopharma Corp (NASDAQ:ABUS) rating on Friday, August 7. Wedbush has “Outperform” rating and $20 target. The stock has “Buy” rating by Chardan Capital Markets on Friday, August 4. The rating was initiated by Chardan Capital Markets on Monday, May 16 with “Sell”. The firm earned “Outperform” rating on Wednesday, February 1 by Wedbush. See Arbutus Biopharma Corp (NASDAQ:ABUS) latest ratings:

04/08/2017 Broker: Chardan Capital Markets Rating: Buy Maintain
04/04/2017 Broker: Chardan Capital Markets Old Rating: Neutral New Rating: Buy Old Target: $3.00 New Target: $6.00 Upgrade

The stock decreased 1.19% or $0.05 on September 1, reaching $4.15. About 49,055 shares traded. Arbutus Biopharma Corp (NASDAQ:ABUS) has declined 2.31% since September 4, 2016 and is downtrending. It has underperformed by 19.01% the S&P500.

Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The company has market cap of $228.36 million. The Firm is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection , a disease of the liver caused by the hepatitis B virus (HBV). It currently has negative earnings. It is developing a pipeline focused on advancing Ribo Nucleic Acid interference therapeutics (RNAi) using its Lipid Nanoparticle technology.

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our daily email newsletter.


Leave a Reply

Your email address will not be published. Required fields are marked *

*

4 × 4 =